Clinical trialPhase 1 / Phase 2Active not recruiting
Radiation Therapy in Combination With Durvalumab for People With Pancreatic Cancer
A Phase I/II Study of Durvalumab (Medi 4736) and Stereotactic Ablative Body Radiotherapy in Locally Advanced Pancreatic Adenocarcinoma
- Outcome
- Ongoing
- Phase
- Phase 1 / Phase 2
- Status
- Active not recruiting
- Study type
- Interventional
- Start
- 14 August 2020
- Expected end
- September 2027
- Enrollment
- 18 participants
- Sites
- 7
- Primary outcomes
- Number of participants with dose limiting toxicities in the first 10 weeks of treatment; Progression Free Survival; Proportion of participants who have resectable disease; Progression Free Survival (Phase II)
- Sponsor
- Other
- Results posted
- No
- Last update
- 9 October 2026
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
The purpose of this study is to find out if combining durvalumab with standard stereotactic ablative radiotherapy (SABR) is an effective treatment for people with locally advanced or borderline resectable pancreatic cancer. The researchers will also look at the safety of the combination treatment and any side effects it causes.